⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
LDL-Lowering Therapies for Prevention
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-03 — IL-21R blockade reduces inflammation and atherosclerosis in LDL receptor deficient mice.: cross-connection with il-21r-blockade: Preclinical atherosclerosis model (Ldlr-/- mice) suggests IL-21R blockade addresses residual inflammatory risk that persists after LDL lowering, positioning it as a potential complement rather than substitute for lipid-directed prevention. (novelty: 3)
- 2026-09-14 — #407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.: Attia podcast #407 with lipidologist Michael Davidson (expert-media interview, no new primary data) argues that applying existing LDL-lowering strategies earlier in life could reduce both cardiovascular disease and Alzheimer’s risk, with emphasis on APOE4 carriers and pipeline lipid therapies. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
#407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.
14-sep-2026
novelty 3
per-area 3
strengthens